Scleroderma
Raúl Fleischmajer(Hahnemann University Hospital), F. Leonard(Centre Hospitalier Universitaire de Reims), B Kalis(Centre Hospitalier Universitaire de Reims), Cornelia Mauch(University Hospital Cologne), V. Azemar(Centre Hospitalier Universitaire de Reims), O. Riche(Centre Hospitalier Universitaire de Reims), Denny L. Tuffanelli(University of California, San Francisco), Brigitte Lankat–Buttgereit(Philipps University of Marburg), Thomas Krieg(University of Cologne), Sławomir Majewski(Medical University of Warsaw), Z. Stava(Karlovac University of Applied Sciences), U F Haustein(Leipzig University), K Herrmann(Leipzig University), N.R. Rowell(Leeds General Infirmary), S Jabłońska, Karin Scharffetter(Ludwig-Maximilians-Universität München)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Epithelial-Mesenchymal Interactions
|Science|1967|1.2k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869